To determine if you have non-small cell lung cancer, your healthcare provider will ... Your provider may also recommend a ...

Non-small cell lung cancer (NSCLC) is the most common type of ... These follow-ups will likely include computed tomography ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

which aligns with the circumstances observed in non-small cell lung cancer. In view of these findings, we believe that PSRC1 may be a potential therapeutic target for SCLC.” “Moreover ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

The five-year relative survival rate of small cell lung cancer—the odds that a cancer patient will live another five years compared to a non-patient—ranges from 7% to 30% depending on the ...

Read more about A trial looking at a drug called UCB4594 for cancer that has spread A trial looking at MK-2870 for non small cell lung cancer (MK-2870-007) This trial is comparing the combination of ...